Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

yousif mahmood hussain pharmacy - sulphasalazine - gastro-resistant tablet - 500

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmacia laboratories limited - sulfasalazine - suppositories - 500 milligram

Malta - English - Medicines Authority

sofar s.p.a via isonzo 8, 20135 - milano, italy - mesalazine - gastro-resistant tablet - mesalazine 400 mg - antidiarrheals, intestinal antiinflammatory/antiinfective agents

Canada - English - Health Canada

pfizer canada ulc - sulfasalazine - enema - 3g - sulfasalazine 3g - sulfonamides

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - sulfasalazine - suppository - 500mg

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

100's bottle -

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

100's bottle -

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.25mg;  ;  ;  ;  ; digoxin 0.25mg - tablet - 0.25 mg - active: digoxin 0.25mg         excipient: lactose monohydrate magnesium stearate maize starch pregelatinised maize starch purified water rice starch active: digoxin 0.25mg excipient: lactose monohydrate magnesium stearate maize starch purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.0625mg;  ;  ;  ;  ; digoxin 0.0625mg - tablet - 0.0625 mg - active: digoxin 0.0625mg         excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone pregelatinised maize starch purified water rice starch active: digoxin 0.0625mg excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - tioguanine 40mg - tablet - 40 mg - active: tioguanine 40mg excipient: acacia lactose monohydrate magnesium stearate potato starch stearic acid - lanvis is indicated primarily for the treatment of acute leukaemias especially:- · acute myelogenous leukaemia · acute lymphoblastic leukaemia